Tom Nguyen - Concepedia

Author

Tom Nguyen

Also Known As

T Nguyen, T. Nguyen, T.T.T. Nguyen, Thanh Vy Nguyễn, Thi Nam Phuong Nguyen, Tom Nguyen, Tom T Nguyen, Tom T. Nguyen, Tran Ngoc Anh Nguyen, Tân Văn Nguyễn

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Brigham and Women's Hospital University of Colorado Denver Harvard University Massachusetts General Hospital

About

Tom Nguyen is an author at Dana-Farber Cancer Institute specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	434
2	Health Sciences	3	3	209
3	Cell Biology	2	2	177
4	Natural Sciences	1	1	22
5	Biochemistry	1	1	22

Tom Nguyen

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC Gonzalo Recondo, Magda Bahcall, Liam F. Spurr, Clinical Cancer Research	2020	210
Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer Xinan Wang, Biagio Ricciuti, Tom Nguyen, Cancer Research	2021	155
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma Natalie I. Vokes, Emily S. Chambers, Tom Nguyen, Journal of Thoracic Oncology Tumor HeterogeneityMedicineEgfr-mutant Lung AdenocarcinomaCancer GenomicsBronchial Neoplasm	2022	142
Expression and Regulation of Chemokines in Murine and Human Type 1 Diabetes Suparna A. Sarkar, Catherine E. Lee, Francisco Victorino, Diabetes	2011	136
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer Ibiayi Dagogo‐Jack, Pablo Martínez, Beow Y. Yeap, Clinical Cancer Research	2018	122
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer Biagio Ricciuti, Joao V. Alessi, Arielle Elkrief, Annals of Oncology Immunophenotypic CorrelatesOncologyMedicinePathologyCancer Genomics	2022	93
A novel human <i>IL2RB</i> mutation results in T and NK cell–driven immune dysregulation Isabel Z. Fernandez, Ryan M. Baxter, Josselyn E. Garcia‐Perez, The Journal of Experimental Medicine	2019	92
Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non–Small-Cell Lung Cancer David M. Jackman, Yichen Zhang, Carole Kathleen Dalby, Journal of Oncology Practice	2017	72
Comprehensive assessment of chemokine expression profiles by flow cytometry Jens Eberlein, Tom Nguyen, Francisco Victorino, Journal of Clinical Investigation	2010	64
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer Xinan Wang, Biagio Ricciuti, Joao V. Alessi, JNCI Journal of the National Cancer Institute	2021	64

Page 1